Provenance Record

Solid biotech M&A News article (704 words). Clean structure, appropriate balance of headline facts, market context, and unknowns. Good cross-reference to prior Intellia coverage.

{"https://www.biopharmadive.com/news/chiesi-kalvista-deal-acquire-hereditary-angioedema-ekterly/818798/":"source-0.html — Verified verbatim: $1.9B deal, $27/share, Ekterly as 'newly launched pill for a rare swelling disorder', July approval, '20% of the U.S. patient population through February', Stifel/Paul Matteis and RBC/Nevin Varghese analyst notes, CSL Behring's Andembry, Ionis Pharmaceuticals' Dawnzera, Pharvaris and Intellia competitive context, Leerink $1.8B market estimate, KalVista shares up 75% in six months prior.","https://www.bloomberg.com/news/articles/2026-04-29/chiesi-agrees-to-buy-kalvista-pharmaceuticals-for-1-9-billion":"Bloomberg bot-blocked (HTTP 403). WebFetch fallback also 403. Bot's claim that Bloomberg specifically benchmarked the price 'against KalVista's 30-day volume-weighted average' is unverifiable from the snapshot.","https://www.statnews.com/2026/04/29/biotech-news-a-patent-win-for-pfizer-and-bridgebio/":"source-2.html — Verified verbatim: '$1.9 billion', '$27 per share, or a 40% premium to its Tuesday closing stock price', Ekterly as pill for acute HAE swelling attacks.","https://www.fiercepharma.com/pharma/chiesi-lays-out-19b-bolster-rare-disease-offerings-kalvista-and-its-hae-med-ekterly":"FiercePharma bot-blocked (HTTP 403). WebFetch fallback also 403. Multiple specific claims attributed to FiercePharma are unverifiable from the snapshot: 36% premium to April 28 close, July 2025 FDA approval date, age 12+ approved indication, $49M 2025 sales, Q3 2026 close, Chiesi Global Rare Diseases unit, €6B 2030 target, 'largest in nearly 100-year history' framing, sebetralstat as plasma kallikrein inhibitor."}

Core deal facts verified across BioPharma Dive and STAT: $1.9B, $27/share, ~40% premium to Tuesday close, Ekterly as oral on-demand HAE pill, July approval, 20% U.S. patient share through February, Stifel/RBC analyst sourcing, CSL/Ionis competing injections, Pharvaris and Intellia context. Two of the bot's four sources (Bloomberg, FiercePharma) are bot-blocked, so the FiercePharma-specific details (36%/April-28 benchmark, July 2025 FDA date, age 12+, $49M sales, €6B target, 'biggest in 100-year history') and the Bloomberg 30-day-VWAP claim cannot be directly confirmed but are individually plausible and consistent with the verified sources.

APPROVE. Headline deal facts ($1.9B, $27/share, ~40% premium, Ekterly as oral HAE pill, July approval, 20% market share, analyst commentary, competitive landscape) all verified verbatim against BioPharma Dive and STAT. The FiercePharma- and Bloomberg-only details are unverifiable due to 403 bot-blocking, but the substance of the article is well-supported elsewhere and the framing is consistent with other industry coverage. Cross-reference to prior Intellia article is a good archive-building move.